Gene therapy of metachromatic leukodystrophy

Expert Opinion on Biological Therapy

Volumn 5, Issue 1, 2005, Pages 55-65

  Matzner, Ulrich ^a   Gieselmann, Volkmar ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Arylsulfatase A; Gene therapy; Lysosomal storage disease; Mannose 6 phosphate; Metachromatic leukodystrophy

Indexed keywords

ARYLSULFATASE; COMPLEMENTARY DNA; LENTIVIRUS VECTOR; MANNOSE 6 PHOSPHATE; RETROVIRUS VECTOR; SPHINGOLIPID; SULFATIDE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; BIOCHEMISTRY; BONE MARROW TRANSPLANTATION; BRAIN FUNCTION; CELL DIVISION; CELL TYPE; DEMYELINATION; ENZYME DEFICIENCY; ENZYME SPECIFICITY; GENE OVEREXPRESSION; GENE THERAPY; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; KNOCKOUT MOUSE; LEUKODYSTROPHY; LYSOSOME STORAGE DISEASE; METACHROMATIC LEUKODYSTROPHY; NEUROLOGIC DISEASE; REVIEW;

ANIMALS; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; LEUKODYSTROPHY, METACHROMATIC;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; LENTIVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 12244301598     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.1.55     Document Type: Review

References (59)

1. GUSTAVSON KH, HAGBERG B: The incidence and genetics of metachromatic leucodystrophy in northern Sweden. Acta Paediatr. Scand. (1971) 60(5):585-590.
2. HEIM P, CLAUSSEN M, HOFFMANN B et al.: Leukodystrophy incidence in Germany. Am. J. Med. Genet. (1997) 71(4):475-478.
3. VON FIGURA K, GIESELMANN V, JAEKEN J: Metachromatic leukodystrophy. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (Eds), McGraw-Hill, New York, USA (2001):3695-3724. A comprehensive review summarising the genetics and pathology of MLD, the biochemistry of ASA, and therapy approaches in ASA knockout mice.
4. SANDHOFF K, KOLTER T, HARZER K: Sphingolipid activator proteins. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (Eds), McGraw-Hill, New York, USA (2001):3371-3388.
5. ISHIBASHI T, DUPREE JL, IKENAKA K et al.: A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J. Neurosci. (2002) 22(15):6507-6514.
6. HIRAHARA Y, BANSAL R, HONKE K et al.: Sulfatide is a negative regulator of oligodendrocyte differentiation: development in sulfatide-null mice. Glia (2004) 45(3):269-277.
7. HESS B, SAFTIG P, HARTMANN D et al.: Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc. Natl. Acad. Sci. USA (1996) 93(25):14821-14826. Describes the construction of the ASA knockout mouse model for MLD.
8. GIESELMANN V, FRANKEN S, KLEIN D et al.: Metachromatic leukodystrophy: consequences of sulphatide accumulation. Acta Paediatr. Suppl. (2003) 92(443):74-79. A recent review on the phenotype and molecular pathology of ASA knockout mice.
9. SCHOTT I, HARTMANN D, GIESELMANN V, LULLMANN-RAUCH R: Sulfatide storage in visceral organs of arylsulfatase A-deficient mice. Virchows Arch. (2001) 439(1):90-96.
10. WITTKE D, HARTMANN D, GIESELMANN V, LULLMANN-RAUCH R: Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distribution. Acta Neuropathol. (Berl.) (2004) 108(4):261-271.
11. D'HOOGE R, COENEN R, GIESELMANN V, LULLMANN-RAUCH R, DE DEYN PP: Decline in brainstem auditory-evoked potentials coincides with loss of spiral ganglion cells in arylsulfatase A-deficient mice. Brain Res. (1999) 847(2):352-356.
12. CONSIGLIO A, QUATTRINI A, MARTINO S et al.: In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. (2001) 7(3):310-316. Describes the high therapeutic potential of lentivirally mediated in vivo gene therapy.
13. D'HOOGE R, HARTMANN D, MANIL J, COLIN F, GIESELMANN V, DE DEYN PP: Neuromotor alterations and cerebellar deficits in aged arylsulfatase A-deficient transgenic mice. Neurosci. Lett. (1999) 273(2):93-96.
14. D'HOOGE R, VAN DAM D, FRANCK F, GIESELMANN V, DE DEYN PP: Hyperactivity, neuromotor defects, and impaired learning and memory in a mouse model for metachromatic leukodystrophy. Brain Res. (2001) 907(1-2):35-43.
15. NEUFELD EF, MUENZER J: The mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), Mc Graw-Hill, New York, USA (1989):1565-1587.
16. STORCH S, BRAULKE T: Transport of lysosomal enzymes. In: Lysosomes. Saftig P (Ed.), Landes Bioscience, Georgetown, TX, USA. (In Press). A review describing the M6P-dependent targeting of lysosomal enzymes.
17. CHAO HH, WAHEED A, POHLMANN R, HILLE A, VON FIGURA K: Mannose 6-phosphate receptor dependent secretion of lysosomal enzymes. EMBO J. (1990) 9(11):3507-3513. Demonstrates that a substantial faction of ASA is delivered from cells.
18. NEUFELD EF, FRATANTONI JC: Inborn errors of mucopolysaccharide metabolism. Science (1970) 169(941):141-146. Pioneering work that defines cross-correction as the mutual exchange of corrective factors secreted from two different LSD cell types.
19. KORNFELD S, SLY WS: I-cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinder KW, Vogelstein B (Eds), McGraw-Hill, New York, USA (2001):3469-3482.
20. BARTON NW, FURBISH FS, MURRAY GJ, GARFIELD M, BRADY RO: Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl. Acad. Sci. USA (1990) 87(5):1913-1916. The first proof-of-principle for the efficacy of enzyme replacement therapy in a LSD.
21. BROOKS DA: Alpha-L-iduronidase and enzyme replacement therapy for mucoporysaccharidosis I. Expert Opin. Biol. Ther. (2002) 2(8):967-976.
22. BRADY RO, MURRAY GJ, MOORE DF, SCHIFFMANN R: Enzyme replacement therapy in Fabry disease. J. Inherit. Metab. Dis. (2001) 24(Suppl. 2):18-24.
23. AMALFITANO A, BENGUR AR, MORSE RP et al.: Recombinant human acid-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a Phase I/II clinical trial. Genet. Med. (2001) 3:132-138.
24. VAN DEN HOUT JM, KAMPHOVEN JH, WINKEL LP et al.: Long-term intravenous treatment of Pompe disease with recombinant human-glucosidase from milk. Pediatrics (2004) 113:e448-e457.
25. LEINEKUGEL P, MICHEL S, CONZELMANN E, SANDHOFF K: Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum. Genet. (1992) 88(5):513-523. Demonstrates that low residual ASA activities are sufficient to prevent MLD.
26. PENZIEN JM, KAPPLER J, HERSCHKOWITZ N et al.: Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease. Am. J. Hum. Genet. (1993) 52(3):557-564. Confirms the data of the previous study.
27. WALKLEY SU, THRALL MA, DOBRENIS K et al.: Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc. Natl. Acad. Sci. USA (1994) 91(8):2970-2974. The most successful BMT therapy is an animal model for a LSD so far.
28. LAWSON LJ, PERRY VH, GORDON S: Turnover of resident microglia in the normal adult mouse brain. Neuroscience (1992) 48(2):405-415.
29. KRALL WJ, CHALLITA PM, PERLMUTTER LS, SKELTON DC, KOHN DB: Cells expressing human glucocerebrosidase from a retroviral vector repopulate macrophages and central nervous system microglia after murine bone marrow transplantation. Blood (1994) 83(9):2737-2748.
30. KENNEDY DW, ABKOWITZ JL: Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood (1997) 90(3):986-993.
31. WALKLEY SU, DOBRENIS K: Bone marrow transplantation for lysosomal diseases. Lancet (1995) 345:1382-1383.
32. DOBRENIS K, WENGER DA, WALKLEY SU: Extracellular release of lysosomal glycosidases in cultures of cat microglia. Mol. Biol. Cell (1994) 5:113a.
33. BIFFI A, DE PALMA M, QUATTRINI A et al.: Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified haematopoietic stem cells. J. Clin. Invest. (2004) 113(8):1118-1129. Describes the therapeutic potential of lentivirally mediated BMSC-GT is a mouse model for MLD.
34. OHASHI T, WATABE K, SATO Y, SAITO I, BARRANGER JA, ETO Y: Successful transduction of oligodendrocytes and restoration of arylsulfatase A deficiency in metachromatic leukodystrophy fibroblasts using an adenovirus vector. Gene Ther. (1995) 2(7):443-449.
35. OHASHI T, WATABE K, SATO Y et al.: Gene therapy for metachromatic leukodystrophy. Acta Paediatr. Jpn. (1996) 38(2):193-201.
36. WEI JF, WEI FS, SAMULSKI RJ, BARRANGER JA: Expression of the human glucocerebrosidase and arylsulfatase A genes in murine and patient primary fibroblasts transduced by an adeno-associated virus vector. Gene Ther. (1994) 1(4):261-268.
37. ROMMERSKIRCH W, FLUHARTY AL, PETERS C, VON FIGURA K, GIESELMANN V: Restoration of arylsulphatase A activity in human-metachromatic-leucodystrophy fibroblasts via retroviral-vector-mediated gene transfer. Biochem. J. (1991) 280(Pt 2):459-461.
38. OHASHI T, ETO Y, LEARISH R, BARRANGER JA: Correction of enzyme deficiency in metachromatic leukodystrophy fibroblasts by retroviral-mediated transfer of the human arylsulphatase A gene. J. Inherit. Metab. Dis. (1993) 16(5):881-885.
39. LEARISH R, OHASHI T, ROBBINS PA et al.: Retroviral gene transfer and sustained expression of human arylsulfatase A. Gene Ther. (1996) 3(4):343-349.
40. SANGALLI A, TAVEGGIA C, SALVIATI A, WRABETZ L, BORDIGNON C, SEVERINI GM: Transduced fibroblasts and metachromatic leukodystrophy lymphocytes transfer arylsulfatase A to myelinating glia and deficient cells in vitro. Hum. Gene Ther. (1998) 9(14):2111-2119.
41. TSUTSUDAASANO A, MIGITA M, TAKAHASHI K, SHIMADA T: Transduction of fibroblasts and CD34+ progenitors using a selectable retroviral vector containing cDNAs encoding arylsulfatase A and CD24. J. Hum. Genet. (2000) 45(1):18-23.
42. MATZNER U, HABETHA M, GIESELMANN V: Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells. Gene Ther. (2000) 7:805-812. Proof that the human ASA can substitute for the murine enzyme and compensate the catabolic defect of ASA-deficient mouse cells.
43. MATZNER U, HARZER K, LEARISH RD, BARRANGER JA, GIESELMANN V: Long-term expression and transfer of arylsulfatase A into brain of arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector. Gene Ther. (2000) 7(14):1250-1257. Demonstrates the transfer of extraordinary high levels of ASA into the CNS by BMSC-GT.
44. MATZNER U, HARTMANN D, LULLMANN-RAUCH R et al.: Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. Gene Ther. (2002) 9(1):53-63. Describes the therapeutic potency of retrovirally mediated BMSC-GT in a mouse model for MLD.
45. EMERMAN M, TEMIN HM: Genes with promoters in retrovirus vectors can be independently suppressed by an epigeneric mechanism. Cell (1984) 39(3 Pt 2):449-467.
46. PESTOVA TV, KOLUPAEVA VG, LOMAKIN IB et al.: Molecular mechanisms of translation initiation in eukaryotes. Proc. Natl. Acad. Sci. USA (2001) 98(13):7029-7036.
47. MUSCHOL N, MATZNER U, TIEDE S, GIESELMANN V, ULLRICH K, BRAULKE T: Secretion of phosphomannosyl-deficient arylsulphatase A and cathepsin D from isolated human macrophages. Biochem. J. (2002) 368(Pt 3):845-853. Demonstrates the expression of uptake-incompetent ASA by cultured cells of the monocyte-phagocyte system.
48. D'AZZO A: Gene transfer strategies for correction of lysosomal storage disorders. Acta Haematol. (2003) 110(2-3):71-85. An excellent review summarising important aspects of gene therapy for LSDs.
49. MATZNER U: Therapy of lysosomal storage diseases. In: Lysosomes. Saftig P (Ed.), Landes Bioscience, Georgetown, TX, USA. (In Press). A review also dealing with possible alternatives to gene therapy.
50. DHAMI R, SCHUCHMAN EH: Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J. Biol. Chem. (2004) 279(2):1526-1532. This report demonstrates impaired endocytosis in certain sphingolipidosis cells.
51. MIRANDA SR, HE X, SIMONARO CM et al.: Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. (2000) 14:1988-1995.
52. MARTINO S, EMILIANI C, TANCINI B et al.: Absence of metabolic cross-correction in Tay-Sachs cells: implications for gene therapy. J. Biol. Chem. (2002) 277(23):20177-20184. Demonstrates defective lysosomal targeting in certain sphingolipidosis cells.
53. KLEIN D, FOGH J, MUSCHOL N, BRAULKE T, GIESELMANN V, MATZNER U: Enzyme substitution in a cell culture and a mouse model for metachromatic leukodystrophy. International Symposium on Lysosomal Disorders - Diseases, Treatment and Pathophysiological Aspects. Fulda, Germany (2003) (scientific paper in preparation). The presented data demonstrate normal endocytic routing of ASA in MLD cells leading to cross-correction of the catabolic defect.
54. MATZNER U, SCHESTAG F, HARTMANN D et al.: Bone marrow stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type cells. Hum. Gene Ther. (2001) 12(9):1021-1033. Indicates that efficient treatment of MLD by gene therapy requires phospholylated ASA.
55. VOGLER C, GALVIN N, LEVY B et al.: Transgene produces massive overexpression of human beta-glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors. Proc. Natl. Acad. Sci. USA (2003) 100(5):2669-2673.
56. IOANNOU YA, BISHOP DF, DESNICK RJ: Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion. J. Cell Biol. (1992) 119(5):1137-1350.
57. DIERKS T, SCHMIDT B, BORISSENKO LV et al.: Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell (2003) 113(4):435-444.
58. ANSON DS, MULLER V, BIELICKI J, HARPER GS, HOPWOOD JJ: Overexpression of N-acetylgalactosamine-4-sulphatase induces a multiple sulphatase deficiency in mucoporysaccharidosis-type-VI fibroblasts. Biochem. J. (1993) 294(Pt 3):657-662.
59. OHASHI T, MATALON R, BARRANGER JA, ETO Y: Overexpression of arylsulfatase A gene in fibroblasts from metachromatic leukodystrophy patients does not induce a new phenotype. Gene Ther. (1995) 2(6):363-368.